Registered Clinical Trial

Noah Tech Clinical Trial
NCT07214974

Early Phase 1 research study evaluating community-based MCI screening and investigational interventions. Not yet recruiting — estimated start September 2026.

View on ClinicalTrials.gov

Last synced with ClinicalTrials.gov: July 1, 2026

NCT Identifier

NCT07214974

Not Yet Recruiting

Clinical Trial NCT07214974

Advancing brain health through rigorous, ethical, and innovative clinical research.

Important study information: This page describes a clinical research study, not an approved treatment program. Stem cell therapy and wearable brain-computer interface (BCI) devices used in this trial are investigational and are not FDA-approved for this indication. Participation is voluntary, may involve risks and burdens (including multi-year follow-up), and provides no guarantee of benefit. Enrollment requires separate eligibility screening and an IRB-approved Informed Consent Form.

Study Overview

This Early Phase 1 trial (NCT07214974) evaluates community-based early detection of mild cognitive impairment (MCI) and targeted investigational interventions in adults aged 55 and older. The study uses a randomized, parallel-assignment, double-blind design with four arms: control (placebo comparator), structured wellness care, investigational stem cell therapy, and investigational wearable BCI device therapy.

Source of truth: ClinicalTrials.gov record NCT07214974 (last synced July 1, 2026).

Key Study Information

Phase

Early Phase 1

Status

Not Yet Recruiting

Enrollment

600 (estimated)

Follow-up

Up to 5 years

Est. Start

September 2026

Sponsor

Noah Tech, Corp.

Conditions & Interventions

Population: Adults aged 55+ in U.S. urban/suburban communities; MCI screening context.

Study arms:

Control (placebo comparator)
Structured wellness care
Investigational stem cell therapy (experimental)
Investigational wearable BCI device (experimental)

Design: Randomized, parallel assignment, double-blind (participants and outcome assessors). FDA-regulated drug and device study.

Primary Outcomes

MoCA change: Mean change from baseline in Montreal Cognitive Assessment (MoCA) total score (baseline through up to 5 years).

Dementia progression: Proportion of participants progressing from MCI to dementia, assessed annually up to 5 years.

Additional measures: Neuropsychological battery scores, quality of life (SF-36), and community screening detection rates per the registered protocol.

Eligibility Summary

Key inclusion criteria (summary): Age 55+; U.S. urban/suburban resident; able to provide informed consent; willing to participate in long-term follow-up; able to complete cognitive screening; no prior formal dementia diagnosis.

Key exclusion criteria (summary): Under age 55; current dementia diagnosis (see full protocol for complete criteria).

Full eligibility criteria are listed on ClinicalTrials.gov.

Contact, Location & Pre-Screening

Study contact: Trial Team — info@noahtech.life | (917) 740-0918

Listed study location (PRS): First Presbyterian Church, Palisades Park, NJ 07650, United States.

Express Interest

Pre-screening interest only — does not enroll you in the study.

IRB documentation: Website recruitment materials for NCT07214974 are under IRB review (status: pending).
Recruitment materials version: WEB-REC-001 v1.0

Interested in Trial Pre-Screening?

Submit an interest form for NCT07214974. This is not enrollment and does not guarantee study participation.